Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study

BACKGROUND: Clinical studies demonstrate that ivacaftor (IVA) improves health-related quality of life (HRQoL) in patients aged ≥6 years with cystic fibrosis (CF). The real-world impact of IVA and standard of care (SOC) in groups of patients with G551D and F508del mutations, respectively, was assesse...

Descripción completa

Detalles Bibliográficos
Autores principales: Bell, Scott C., Mainz, Jochen G., MacGregor, Gordon, Madge, Susan, Macey, Julie, Fridman, Moshe, Suthoff, Ellison D., Narayanan, Siva, Kinnman, Nils
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693259/
https://www.ncbi.nlm.nih.gov/pubmed/31409396
http://dx.doi.org/10.1186/s12890-019-0887-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693259/
https://www.ncbi.nlm.nih.gov/pubmed/31409396
http://dx.doi.org/10.1186/s12890-019-0887-6

Ejemplares similares